Supplementary Material



Supplementary MaterialInvestigational sitesUS Investigational sitesHighlands Oncology Group, Fayetteville, ARGenesis Cancer Center, Hot Springs, AZIronwood Cancer & Research Center, Chandler, AZBeverly Hills Cancer Center, Beverly Hills, CASt Joseph Heritage Healthcare, Santa Rosa, CASinging River Health System, Whittier, CAInnovative Clinical Research Institute (ICRI), Whittier, CACompassionate Cancer Care Medical Group, Corona, CAMemorial Hospital, Colorado Springs, COCancer Care & Hematology, Fort Collins, CORocky Mountain Cancer Center, Denver, COFlorida Cancer Specialists, Fort Myers, FLFlorida Cancer Specialists, West Palm Beach, FLFlorida Cancer Specialists, St. Petersburg, FLBoca Raton Regional Hospital Lynn Cancer Institute, Boca Raton, FLSylvester Comprehensive Cancer Center, Miami, FLSara Cannon/Florida Cancer Specialist-South, Fort Myers, FLSara Cannon/Florida Cancer Specialist-East, West Palm Beach, FLSara Cannon/Florida Cancer Specialist-North, Tavares, FLWinship Cancer Institute, Emory University, Atlanta, GANorthside Hospital, Inc., Atlanta, GAPiedmont Cancer Institute, Atlanta, GAUniversity Cancer & Blood Center, Athens, GANorton Cancer Institute, Norton Healthcare Pavilion, Louisville, KYThe Center for Cancer and Blood Disorders, Bethesda, MDSaint Luke's Hospital, Kansas City, MOUniversity of North Carolina at Chapel Hill, Chapel Hill, NCRegional Medical Oncology Center, Wilson, NCDartmouth-Hitchcock Medical Center, Lebanon, NHSummit Medical Group, P.A., Morristown, NJUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NMRoswell Park Cancer Institute, Buffalo, NYGabrail Cancer Center Research, Canton, OHStephenson Cancer Center, Oklahoma City, OKGuthrie Medical Group, Sayre, PAThomas Jefferson University Hospital, Philadelphia, PAGreenville Health System, Greensville, SCSpartansburg Medical Center, Spartansburg, SCSara Cannon/Tennessee Oncology, Chattanooga, TNSara Cannon/Tennessee Oncology-Nashville, NashvilleUniversity of Tennessee Medical Center, Knoxville, TNMeharry Medical College, Nashville, TNTennessee Cancer Specialists, Knoxville, TNTennessee Oncology, Nashville, TNTexas Oncology, Tyler, TXThe University of Texas MD Anderson Cancer Center, Houston, TXMillennium Oncology, Houston, TXVirginia Cancer Specialists, Fairfax, VAVirginia Oncology Associates, Norfolk, VABlue Ridge Cancer Care, Blacksburg, VAFairfax-Northern Virginia Hematology-Oncology PC, Arlington, VANorthwest Cancer Specialists, Vancouver, WAEx-USA Investigational sitesAZ Klina, Antwerp, BelgiumComplex Oncology Center, Burgas, BulgariaMultiprofile Hospital for Active Treatment, Serdika, BulgariaTokuda Hospital, Sofia, BulgariaUniversity Hospital Centre Zagreb, CroatiaEast Tallinn Central Hospital Ltd., Tallinn, EstoniaTartu University Hospital, Tartu, EstoniaCHU de Rennes - Hopital de Pontchaillou, FranceCentre Hospitalier de la c?te Basque, Bayonne, FranceLLC ARENSIA Exploratory Medicine, GeorgiaGeorgia LTD Research Institute of Clinical Medicine, Tbilisi, GeorgiaGeorgia, LTD Clinical Oncology Center, GeorgiaGeorgia LTD Institute for Personalized Medicine, Tbilisi, GeorgiaLTD Cancer Research Centre, Tbilisi, GeorgiaVeszprem Megyei Tudogyogyintezet, HungaryHetenyi Geza Korhaz, HungaryOrszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, HungaryDaugavpils Regional Hospital, Daugavpils, LatviaP. Stradins Clinical University Hospital, Riga, LatviaRiga East University Hospital, LLC, Riga, LatviaUniversity Clinic of Radiotherapy and Oncology, Skopje, Republic of MacedoniaARENSIA Exploratory Medicine Phase I Unit, The Institute of Oncology, MoldovaWojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, PolandSamodzielny Publiczny Zespol Gruzlicy i Chorob Pluc w Olsztynie, PolandInstitute for Pulmonary Diseases of Vojvodina, SerbiaClinical Center Nis, SerbiaInstitute for Oncology and Radiology of Serbia, SerbiaClinical Center of Serbia, SerbiaClinical Hospital Center "Bezanijska Kosa", SerbiaHospital Provincial de Castellon, SpainHgu Gregorio Maranon, SpainHospital de la Santa Creu i Sant Pau, SpainHospital Universitario Fundacion Jimenez Diaz, SpainH.U. Quirón Dexeus, Hospital Universitario, Quirón Dexeus, SpainHospital Teresa Herrera, Xerencia de Xestión Integrada A Coru?a, SpainDnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipro, UkraineChernivtsi Regional Clinical Oncology Center, Chernivtsi, UkraineVolyn Regional Oncology Center, Lutsk, UkraineTernopil Regional Public Clinical Oncology Center, Ternopil, UkraineSumy Regional Clinical Oncology Center, Sumy, UkraineSupplementary MethodsRisk factor subgroups for febrile neutropenia (FN): Age ≥65 yearsPoor nutritional status (if baseline albumin is <3.5 g/dL)Renal dysfunction (if any of the preferred terms [PTs] listed below are present in medical history)Category PTsRenal dysfunctionChronic kidney diseaseDiabetic end-stage renal diseaseEnd-stage renal diseaseRenal impairmentGlomerulonephritis chronicChronic autoimmune glomerulonephritisNephrosclerosisNephrotic syndromeAcute glomerulonephritisCardiovascular disease (if any of the following high-level terms [HLTs] are present in medical history)Category HLTsCardiovascular diseaseHeart failure necrotizing enterocolitisLeft ventricular failureRight ventricular failureIschemic coronary artery disordersCoronary necrosis and vascular insufficiencyMultiple comorbid conditions (if any of the following terms [HLT or PT] are present in medical history)Category PTsMultiple comorbid conditionsChronic kidney diseaseDiabetic end-stage renal diseaseEnd-stage renal diseaseRenal impairmentGlomerulonephritis chronicChronic autoimmune glomerulonephritisNephrosclerosisNephrotic syndromeAcute glomerulonephritisOsteoarthritisBronchitis chronicChronic obstructive pulmonary diseaseAsthma – chronic obstructive pulmonary disease overlap syndromeEmphysemaAsthmaBronchiectasisAutoimmune colitisCrohn’s diseaseColitis ulcerativeMultiple sclerosisHLTsHeart failure necrotizing enterocolitisLeft ventricular failureRight ventricular failureIschemic coronary artery disordersCoronary necrosis and vascular insufficiencyLupus erythematosus and associated conditionsLupus erythematosus (including subtypes)Multiple sclerosis acute and progressiveDuodenal ulcers and perforationGastric ulcers and perforationPeptic ulcers and perforationAcute and chronic thyroiditisThyroid hypofunction disordersThyroid hyperfunction disordersFor patients enrolled in study G1T28-03, an additional factor related to the risk of FN is identified as previous cytotoxic chemotherapy (defined by any of the following prior small cell lung cancer therapies coded by World Health Organization Drug Dictionary [WHO-DD] preferred names)Category WHO-DD Preferred NamesPrevious cytotoxic chemotherapyCarboplatinCisplatinCyclophosphamideDoxorubicinEtoposideIrinotecanLurbinectedinPlatinumPrexasertibVeliparibVincristine ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download